Here is the number that reframes the whole market: since semiconductors peaked on June 22, the iShares Biotechnology ETF (IBB) has climbed more than 20%, while the Health Care Select Sector SPDR Fund (XLV) has gained roughly 16%. Over the same stretch, the iShares Semiconductor ETF (SOXX) has fallen just under 20%. That is a 36-point swing between two sectors that institutional investors treated, for most of the past three years, as if they occupied different planets. They do not. Capital is finite, and it is moving.

What makes this more than a short-term rotation story is where the money was before it showed up in healthcare ETFs. Healthcare funds shed about $21 billion in 2025 alone, according to Morningstar. Healthcare ETFs have taken in about $4.5 billion so far in 2026. Even after the recent surge, healthcare’s performance versus the S&P 500 over the past three years still ranks among the weakest 10% of periods in Sohn’s historical data. The institutional exodus was so deep that the rebound, even after weeks of outperformance, has barely closed the valuation gap the outflows created.

Why This Breakout Is Different

The healthcare rally was already well underway before any single catalyst ignited it, while SOXX was rolling over again after its latest rebound fizzled. Chip bears regained control this week, with sellers stepping in after SOXX had recovered roughly half of its June-to-July drop. That failure to reclaim prior levels matters. When a cyclical recovery attempt fails at the halfway mark, it tends to drive capital toward whatever is already working. Healthcare was already working.

Capital is actively shifting out of high-beta semiconductors and growth names into defensive value, healthcare, and under-owned small caps rather than pushing benchmark indices back toward record highs. That framing, from Prospero.ai’s July trading letters, captures something important: this is not a bet on a macro recovery. It is a bet on a sector change in leadership while the broad index digests the AI trade’s first serious correction.

Semiconductor stocks now make up roughly 42% of the S&P 500 tech sector and about 20% of the full index, meaning passive investors are making a concentrated bet on AI-adjacent chip names. When that concentration unwinds, even partially, it generates outsized flows into sectors that never got crowded. Healthcare was never crowded.

The Earnings Engine

The breakout is not a valuation story dressed up as a fundamental one. The fundamentals are real, and they start with Eli Lilly. Lilly reported second-quarter earnings and revenue that easily beat estimates and raised its full-year sales outlook, as demand for Zepbound and Mounjaro surged. The company now expects 2026 revenue between $85 billion and $87 billion, up from prior guidance of $82 billion to $85 billion.

Lilly posted Q2 2026 non-GAAP EPS of $8.38, exceeding analysts’ expectations of $6.01 by about 39%. A roughly 39% EPS beat for the largest company in the S&P 500 healthcare sector is not a rounding error. It resets the earnings base for analyst models that were already stale. The Zacks consensus for Lilly’s 2026 full-year earnings is $35.67, with 2027 estimates climbing in tandem.

The catalyst beneath Lilly’s numbers is structural. Starting July 1, 2026, some people with Medicare became eligible for coverage of certain weight-loss medications through the new Medicare GLP-1 Bridge. Under the program, eligible beneficiaries pay $50 per month for covered GLP-1 drugs. Lilly CEO David Ricks estimated that global GLP-1 use will rise from approximately 20 million patients at the end of last year to 30 million at the end of 2026. That volume expansion does not require a price increase to drive earnings. It just requires prescriptions, and the coverage expansion is writing them.

Merck offers the value-and-stability counterweight to Lilly’s growth profile. Merck’s first quarter was quietly solid: worldwide sales rose 5% to $16.29 billion, comfortably beating the consensus estimate, with flagship oncology franchise Keytruda generating about $8.0 billion. Two very different companies, two very different earnings profiles, both moving the sector’s aggregate numbers in the same direction.

The M&A Floor Nobody Is Pricing

Beyond earnings, healthcare has a second engine running that semiconductors currently lack: a buy-side bid from large pharma balance sheets sitting on patent cliffs. The strongest momentum came from biopharma, where PwC said pharmaceutical and life sciences deal value topped $65 billion in the first quarter alone, making it the sector’s strongest quarter since 2020. Separate industry tallies put biopharma deal value higher, underscoring just how active the tape has been.

The medtech sector is also extending a period of unusually strong activity. After a rebound in 2025, deal activity stayed elevated in the first half of 2026, with multiple trackers putting announced medtech deal value in the roughly $30 billion range.

Strategic urgency, driven by patent cliffs, pipeline gaps, and strong pharmaceutical balance sheets, is fueling robust deal activity across biopharma, biotech, and medtech, including landmark cross-border transactions and billion-dollar megadeals. A sector with this level of M&A activity has a natural price floor. Acquirers are telling the market what target valuations are worth to them in cash.

PwC expects the second half of 2026 to see continued bolt-on activity in oncology, metabolic disease, vaccines, and radiopharmaceuticals. That pipeline of deals is also a pipeline of acquisition premiums still unpriced in small and mid-cap biotech names.

The Political Tailwind Nobody Wants to Say Out Loud

2026 is a midterm election year, and healthcare has historically tended to hold up better than many other sectors in midterm years, partly because the policy overhangs that haunted the sector, including drug-pricing reform and Affordable Care Act uncertainty, have largely been digested. That is a meaningful edge. It reflects a consistent pattern: regulatory clarity arrives after the legislative calendar clears, and institutions use the window to rebuild positions that fear had driven out.

Bull Case

The bull case rests on three legs that are each independently valid. First: earnings acceleration, led by GLP-1 volume expansion and Medicare coverage opening a new pathway for eligible beneficiaries. Second: M&A support, with pharma balance sheets writing checks at premiums that put a floor under biotech valuations. Third: flows that are still early-stage. Healthcare and biotech are reaching new highs after years of underperformance, while ETF investors are only beginning to come back. For a sector that spent years unloved, an early-stage return of investor interest could give the breakout more room to run.

Bear Case

The risks are real and should not be papered over. Concentration in Eli Lilly creates single-stock risk for XLV. XLV’s heavy weighting in Eli Lilly has allowed it to capture the obesity-drug boom, while its inclusion of medical stalwarts like JNJ provides a defensive floor, but that concentration cuts both ways. Any clinical disappointment, competitive pricing pressure from Novo Nordisk’s oral semaglutide, or Medicare reimbursement revision hits the whole sector’s headline number.

Insurers like UnitedHealth face regulatory headwinds and rising medical loss ratios, making insurance-specific exposure more volatile than the broad sector. A managed care earnings miss heading into Q3 would test the thesis quickly. And if chips stabilize and SOXX reclaims its prior high, the rotation trade loses its relative strength argument in a single session.

What Investors Should Watch Next

Three metrics will tell investors whether this breakout is structural or a two-month relief trade. First, watch weekly ETF flows into XLV and IBB. Todd Sohn of Baird Strategas has noted that healthcare flows are accelerating after dismal demand over the last three years, but the $4.5 billion in 2026 inflows barely offsets a fraction of the roughly $20 billion plus that left in recent years. If flows stall, the momentum argument breaks. Second, watch GLP-1 prescription volume data for Q3. Lilly’s October 29 earnings report is the next scheduled checkpoint on that front, though the company has not formally confirmed the date. Third, watch SOXX. If chip sellers absorb the bounce and the ETF retests its lows, healthcare gets another leg of relative inflow. If SOXX reverses hard, institutional money faces a choice.

Bottom Line

The chip bear market did not just punish semiconductor investors. It created the conditions for one of the cleanest sector rotations in years. Healthcare was cheap on a relative basis, unloved by flows, improving on fundamentals, and now receiving a genuine policy tailwind through Medicare GLP-1 Bridge access. That combination rarely assembles itself this cleanly. The question is not whether the breakout is real. It is whether investors who spent three years avoiding this sector will arrive early enough to matter, or late enough to pay for someone else’s conviction.